JP2019506398A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019506398A5 JP2019506398A5 JP2018538177A JP2018538177A JP2019506398A5 JP 2019506398 A5 JP2019506398 A5 JP 2019506398A5 JP 2018538177 A JP2018538177 A JP 2018538177A JP 2018538177 A JP2018538177 A JP 2018538177A JP 2019506398 A5 JP2019506398 A5 JP 2019506398A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- nos
- group
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 6
- 208000005017 glioblastoma Diseases 0.000 claims 6
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 206010014967 Ependymoma Diseases 0.000 claims 4
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 4
- 208000000172 Medulloblastoma Diseases 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 208000007641 Pinealoma Diseases 0.000 claims 4
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- 201000010536 head and neck cancer Diseases 0.000 claims 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims 4
- 230000003211 malignant effect Effects 0.000 claims 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 206010061424 Anal cancer Diseases 0.000 claims 2
- 206010073128 Anaplastic oligodendroglioma Diseases 0.000 claims 2
- 208000007860 Anus Neoplasms Diseases 0.000 claims 2
- 206010003571 Astrocytoma Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 102000001301 EGF receptor Human genes 0.000 claims 2
- 108060006698 EGF receptor Proteins 0.000 claims 2
- 206010014968 Ependymoma malignant Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010027406 Mesothelioma Diseases 0.000 claims 2
- 201000010133 Oligodendroglioma Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010050487 Pinealoblastoma Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000008938 Rhabdoid tumor Diseases 0.000 claims 2
- 206010073334 Rhabdoid tumour Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 206010043276 Teratoma Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 206010002224 anaplastic astrocytoma Diseases 0.000 claims 2
- 208000014534 anaplastic ependymoma Diseases 0.000 claims 2
- 201000011165 anus cancer Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000006571 choroid plexus carcinoma Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000010932 epithelial neoplasm Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000011610 giant cell glioblastoma Diseases 0.000 claims 2
- 208000002409 gliosarcoma Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 206010027191 meningioma Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 201000004058 mixed glioma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 201000003113 pineoblastoma Diseases 0.000 claims 2
- 206010035059 pineocytoma Diseases 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000009277 Neuroectodermal Tumors Diseases 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 208000013938 anaplastic oligoastrocytoma Diseases 0.000 claims 1
- 229920001222 biopolymer Polymers 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 208000026436 grade III glioma Diseases 0.000 claims 1
- 239000012216 imaging agent Substances 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 201000008205 supratentorial primitive neuroectodermal tumor Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021094240A JP7222024B2 (ja) | 2016-01-21 | 2021-06-04 | 上皮増殖因子受容体変異体ｉｉｉおよびｃｄ３の単一および二重特異性抗体およびそれらの使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662281543P | 2016-01-21 | 2016-01-21 | |
| US62/281,543 | 2016-01-21 | ||
| US201662431766P | 2016-12-08 | 2016-12-08 | |
| US62/431,766 | 2016-12-08 | ||
| PCT/IB2017/050109 WO2017125831A1 (en) | 2016-01-21 | 2017-01-10 | Mono and bispecific antibodies for epidermal growth factor receptor variant iii and cd3 and their uses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021094240A Division JP7222024B2 (ja) | 2016-01-21 | 2021-06-04 | 上皮増殖因子受容体変異体ｉｉｉおよびｃｄ３の単一および二重特異性抗体およびそれらの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019506398A JP2019506398A (ja) | 2019-03-07 |
| JP2019506398A5 true JP2019506398A5 (enExample) | 2020-02-20 |
Family
ID=57838442
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018538177A Pending JP2019506398A (ja) | 2016-01-21 | 2017-01-10 | 上皮増殖因子受容体変異体ｉｉｉおよびｃｄ３の単一および二重特異性抗体およびそれらの使用 |
| JP2021094240A Active JP7222024B2 (ja) | 2016-01-21 | 2021-06-04 | 上皮増殖因子受容体変異体ｉｉｉおよびｃｄ３の単一および二重特異性抗体およびそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021094240A Active JP7222024B2 (ja) | 2016-01-21 | 2021-06-04 | 上皮増殖因子受容体変異体ｉｉｉおよびｃｄ３の単一および二重特異性抗体およびそれらの使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10221242B2 (enExample) |
| EP (1) | EP3405490B1 (enExample) |
| JP (2) | JP2019506398A (enExample) |
| CN (1) | CN109219618B (enExample) |
| CA (1) | CA2954802C (enExample) |
| DK (1) | DK3405490T3 (enExample) |
| ES (1) | ES2904593T3 (enExample) |
| TW (2) | TW201936640A (enExample) |
| WO (1) | WO2017125831A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| ES2904593T3 (es) | 2016-01-21 | 2022-04-05 | Pfizer | Anticuerpos monoespecíficos y biespecíficos para la variante III del receptor del factor de crecimiento epidérmico y CD3 y sus usos |
| BR112018014585A2 (pt) * | 2016-01-21 | 2018-12-11 | Pfizer | receptores de antígeno quiméricos que direcionam o receptor do fator de crescimento epidérmico variante iii |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| CN110913906A (zh) | 2017-05-02 | 2020-03-24 | 默沙东公司 | 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂 |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| US20210032351A1 (en) * | 2017-12-13 | 2021-02-04 | Xdcexplorer (Shanghai) Co., Ltd. | Egfrviii antibody and conjugate, and preparation method and use thereof |
| MX2020008183A (es) | 2018-02-01 | 2020-09-22 | Pfizer | Anticuerpos especificos para cd70 y sus usos. |
| MX2020008184A (es) | 2018-02-01 | 2020-09-22 | Pfizer | Receptores de antigeno quimericos dirigidos a cd70. |
| CN111936516B (zh) * | 2018-03-19 | 2023-03-03 | 上海药明生物技术有限公司 | 新型抗egfr抗体多肽 |
| US11525010B2 (en) * | 2018-05-23 | 2022-12-13 | Pfizer Inc. | Antibodies specific for GUCY2c and uses thereof |
| CN119405833A (zh) | 2018-06-01 | 2025-02-11 | 卫材R&D管理有限公司 | 剪接调节抗体-药物缀合物及其使用方法 |
| CN109265561B (zh) * | 2018-09-25 | 2021-05-25 | 山东兴瑞生物科技有限公司 | 抗EGFRvⅢ安全型嵌合抗原受体、其制备方法、利用其修饰的NK细胞及应用 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| MX2021004356A (es) | 2018-10-18 | 2021-05-31 | Merck Sharp & Dohme Llc | Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas. |
| MA54089A (fr) | 2018-10-31 | 2022-02-09 | Merck Sharp & Dohme | Anticorps anti-pd-1 humain et procédés d'utilisation associés |
| JP7503056B6 (ja) | 2018-11-07 | 2024-07-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｌａｇ３抗体および抗ｐｄ－１抗体の共－製剤 |
| CN113603783B (zh) * | 2018-12-21 | 2022-07-12 | 浙江时迈药业有限公司 | 蛋白酶可切割的双特异性抗体及其用途 |
| CA3131036A1 (en) * | 2019-02-22 | 2020-08-27 | Wuhan Yzy Biopharma Co., Ltd. | Cd3 antigen-binding fragment and application thereof |
| TWI915311B (zh) | 2019-03-29 | 2026-02-21 | 荷蘭商美勒斯公司 | Cd3結合分子 |
| AU2020385991A1 (en) | 2019-11-21 | 2022-06-23 | Unity Biotechnology | Antibodies directed to Tie-2 and methods of use |
| CN111072772B (zh) * | 2019-12-31 | 2023-08-04 | 上海良润生物医药科技有限公司 | 一种肽标签及其在检测或纯化融合蛋白质的应用 |
| CN115379848A (zh) * | 2020-04-01 | 2022-11-22 | 加利福尼亚大学董事会 | 靶向间充质干细胞衍生的癌细胞和间充质干细胞相关疾病的免疫治疗诊断剂 |
| EP4225792A1 (en) | 2020-10-08 | 2023-08-16 | Affimed GmbH | Trispecific binders |
| CN112661844B (zh) * | 2020-11-18 | 2022-05-03 | 贵州医科大学 | 一种靶向EGFRvIII的单链抗体及应用 |
| CN114539418A (zh) * | 2020-11-26 | 2022-05-27 | 上海华奥泰生物药业股份有限公司 | 双特异性抗体及其用途 |
| WO2022166739A1 (en) * | 2021-02-04 | 2022-08-11 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | Antibodies specifically recognizing thymic stromal lymphopoietin and uses thereof |
| JPWO2023286840A1 (enExample) * | 2021-07-16 | 2023-01-19 | ||
| JP2024529381A (ja) | 2021-07-30 | 2024-08-06 | アフィメド ゲーエムベーハー | デュプレックスボディ |
| AU2021467228A1 (en) * | 2021-09-29 | 2024-04-04 | National Research Council Of Canada | Humanized anti-egfrviii antibodies and antigen-binding fragments thereof |
| TW202334221A (zh) | 2021-11-03 | 2023-09-01 | 德商安富美德有限公司 | 雙特異性cd16a結合劑 |
| CN116333117B (zh) * | 2021-12-16 | 2024-04-26 | 徕特康(苏州)生物制药有限公司 | 抗表皮生长因子受体抗体及其制备方法和用途 |
| CN116047081B (zh) * | 2023-01-10 | 2024-02-13 | 北京新源长青生物科技有限公司 | 检测Aβ40、Aβ42的试剂盒与方法 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2025257588A1 (en) | 2024-06-10 | 2025-12-18 | Affimed Gmbh | Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0832980B1 (en) | 1989-01-23 | 2002-06-19 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
| US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| DK0737750T3 (da) | 1989-03-21 | 2003-09-01 | Vical Inc | Ekspression af exogene polynucleotidsekvenser i vertebrater |
| EP0739904A1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| EP1001032A3 (en) | 1989-08-18 | 2005-02-23 | Chiron Corporation | Recombinant retroviruses delivering vector constructs to target cells |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| ZA911974B (en) | 1990-03-21 | 1994-08-22 | Res Dev Foundation | Heterovesicular liposomes |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| AU8295491A (en) | 1990-06-29 | 1992-01-23 | Biosource Technologies Incorporated | Melanin production by transformed microorganisms |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| US5278299A (en) | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| ATE237694T1 (de) | 1991-08-20 | 2003-05-15 | Us Gov Health & Human Serv | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| JP3540315B2 (ja) | 1991-09-23 | 2004-07-07 | メディカル リサーチ カウンシル | キメラ抗体の製造−組合せアプローチ |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| WO1993010260A1 (en) | 1991-11-21 | 1993-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| EP0650370A4 (en) | 1992-06-08 | 1995-11-22 | Univ California | METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES. |
| EP0644946A4 (en) | 1992-06-10 | 1997-03-12 | Us Health | VECTOR PARTICLES RESISTANT TO INACTIVATION BY HUMAN SERUM. |
| WO1994002610A1 (en) | 1992-07-17 | 1994-02-03 | Dana-Farber Cancer Institute | Method of intracellular binding of target molecules |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| DE69308573T2 (de) | 1992-08-17 | 1997-08-07 | Genentech Inc | Bispezifische immunoadhesine |
| US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
| EP0673431A1 (en) | 1992-12-03 | 1995-09-27 | Genzyme Corporation | Gene therapy for cystic fibrosis |
| AU6818094A (en) | 1993-04-22 | 1994-11-08 | Depotech Corporation | Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| EP0705344B8 (en) | 1993-06-24 | 2006-05-10 | Advec Inc. | Adenovirus vectors for gene therapy |
| WO1995007994A2 (en) | 1993-09-15 | 1995-03-23 | Viagene, Inc. | Recombinant alphavirus vectors |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| DE69435223D1 (de) | 1993-10-25 | 2009-09-03 | Canji Inc | Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung |
| HUT75162A (en) | 1993-11-16 | 1997-04-28 | Depotech Corp | Vesicles with controlled release of actives |
| US6436908B1 (en) | 1995-05-30 | 2002-08-20 | Duke University | Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function |
| DE69535669T2 (de) | 1994-05-09 | 2008-12-04 | Oxford Biomedica (Uk) Ltd. | Retrovirale vektoren mit verminderter rekombinationsrate |
| WO1996017072A2 (en) | 1994-11-30 | 1996-06-06 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| DE69739286D1 (de) | 1996-05-06 | 2009-04-16 | Oxford Biomedica Ltd | Rekombinationsunfähige retrovirale vektoren |
| WO1999018792A1 (en) | 1997-10-10 | 1999-04-22 | Johns Hopkins University | Gene delivery compositions and methods |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| DK1575517T3 (da) | 2002-12-24 | 2012-05-14 | Rinat Neuroscience Corp | Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme |
| MXPA05014155A (es) | 2003-06-27 | 2006-05-25 | Abgenix Inc | Anticuerpos dirigidos a los mutantes de delecion de receptor de factor de crecimiento epidermico y sus usos. |
| WO2006113546A2 (en) | 2005-04-15 | 2006-10-26 | Neogenix Oncology, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| EP2010911A4 (en) | 2006-03-31 | 2009-05-13 | Massachusetts Inst Technology | TREATMENT OF EGF RECEPTOR MUTANTS EXPRESSING TUMORS |
| US20100105136A1 (en) | 2006-10-09 | 2010-04-29 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
| WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| CA2813411C (en) | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| US9249217B2 (en) * | 2010-12-03 | 2016-02-02 | Secretary, DHHS | Bispecific EGFRvIII x CD3 antibody engaging molecules |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP3459560B1 (en) | 2011-04-08 | 2021-02-24 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer |
| AU2012340174A1 (en) * | 2011-11-16 | 2014-05-29 | Amgen Inc. | Methods of treating epidermal growth factor deletion mutant VIII related disorders |
| EP2780039B9 (en) | 2011-11-17 | 2018-04-18 | Pfizer Inc | Cytotoxic peptides and antibody drug conjugates thereof |
| JP6154895B2 (ja) * | 2012-06-07 | 2017-06-28 | デューク ユニバーシティー | ヒト二重特異性ＥＧＦＲｖＩＩＩ抗体結合分子 |
| KR20150029714A (ko) | 2012-07-13 | 2015-03-18 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 이중특이적 항체의 공-도입에 의한 ｃａｒ 세포의 활성 증강 |
| AU2013312838B2 (en) | 2012-09-04 | 2018-11-29 | Cellectis | Multi-chain chimeric antigen receptor and uses thereof |
| SG11201505896YA (en) | 2013-02-20 | 2015-09-29 | Novartis Ag | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| US20160017058A1 (en) * | 2013-03-14 | 2016-01-21 | The California Institute For Biomedical Research | Bispecific antibodies and uses thereof |
| CA2917919C (en) * | 2013-07-09 | 2019-07-02 | Duke University | Certain improved human bispecific egfrviii antibody engaging molecules |
| US10195289B2 (en) | 2013-07-31 | 2019-02-05 | Rinat Neuroscience Corp. | Engineered polypeptide conjugates using transglutaminase |
| CN105555804B (zh) | 2013-08-07 | 2020-12-25 | 阿菲姆德股份有限公司 | 对EGFRvIII有特异性的抗体结合位点 |
| WO2015092024A2 (en) | 2013-12-20 | 2015-06-25 | Cellectis | Method of engineering multi-input signal sensitive t cell for immunotherapy |
| RU2017102769A (ru) | 2014-07-29 | 2018-08-28 | Пфайзер Инк. | EGFRvIII СПЕЦИФИЧЕСКИЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРЫ ДЛЯ ИММУНОТЕРАПИИ РАКА |
| HUE057285T2 (hu) | 2015-04-13 | 2022-04-28 | Pfizer | Terápiás ellenanyagok és alkalmazásaik |
| TWI744242B (zh) * | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| ES2904593T3 (es) | 2016-01-21 | 2022-04-05 | Pfizer | Anticuerpos monoespecíficos y biespecíficos para la variante III del receptor del factor de crecimiento epidérmico y CD3 y sus usos |
| BR112018014585A2 (pt) | 2016-01-21 | 2018-12-11 | Pfizer | receptores de antígeno quiméricos que direcionam o receptor do fator de crescimento epidérmico variante iii |
-
2017
- 2017-01-10 ES ES17700749T patent/ES2904593T3/es active Active
- 2017-01-10 WO PCT/IB2017/050109 patent/WO2017125831A1/en not_active Ceased
- 2017-01-10 TW TW108104245A patent/TW201936640A/zh unknown
- 2017-01-10 TW TW106100739A patent/TWI657096B/zh not_active IP Right Cessation
- 2017-01-10 DK DK17700749.9T patent/DK3405490T3/da active
- 2017-01-10 EP EP17700749.9A patent/EP3405490B1/en active Active
- 2017-01-10 CN CN201780015091.8A patent/CN109219618B/zh active Active
- 2017-01-10 JP JP2018538177A patent/JP2019506398A/ja active Pending
- 2017-01-10 US US15/402,807 patent/US10221242B2/en active Active
- 2017-01-12 CA CA2954802A patent/CA2954802C/en active Active
-
2018
- 2018-10-17 US US16/163,243 patent/US11279764B2/en not_active Expired - Fee Related
-
2021
- 2021-06-04 JP JP2021094240A patent/JP7222024B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bordeau et al. | Transient competitive inhibition bypasses the binding site barrier to improve tumor penetration of trastuzumab and enhance T-DM1 efficacy | |
| Cheng et al. | Recent advances in small molecule based cancer immunotherapy | |
| RU2018130088A (ru) | Химерные антигенные рецепторы, нацеливающиеся на вариант iii рецептора эпидермального фактора роста | |
| JP2019506394A5 (enExample) | ||
| MY205503A (en) | Improved antigen binding receptors | |
| RU2014138474A (ru) | Новые модуляторы и способы применения | |
| RU2014138038A (ru) | Фармацевтическая композиция для лечения профилактики рака | |
| JP2016503295A5 (enExample) | ||
| JP2017506217A5 (enExample) | ||
| RU2016147206A (ru) | Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака | |
| RU2016122041A (ru) | Новые анти-клаудин антитела и способы их применения | |
| IL278574B2 (en) | Glycan-interacting compounds and methods of use | |
| JP2013512920A5 (enExample) | ||
| CY1121249T1 (el) | Αντισωμα εναντι του ειδικου προστατικου αντιγονου βλαστικου κυτταρου και χρησεις αυτου | |
| JP2010535713A5 (enExample) | ||
| CA2595610A1 (en) | Antibodies directed to angiopoietin-2 and uses thereof | |
| RU2014138039A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| ZA201901379B (en) | Antigen binding protein against her3 | |
| Dou et al. | ScFv‐decorated PEG‐PLA‐based nanoparticles for enhanced siRNA delivery to Her2+ breast cancer | |
| RU2014108043A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
| CN109923123B (zh) | 具有结合或阻断pd-l1的分子的纳米颗粒及其在治疗癌症中的用途 | |
| Yu et al. | Eradication of growth of HER2-positive ovarian cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse xenograft model | |
| Yu et al. | Synergistic antitumor effects of 9.2. 27-PE38KDEL and ABT-737 in primary and metastatic brain tumors | |
| CN115916839A (zh) | 抗pdl1×egfr的双特异性抗体 | |
| JPWO2022270524A5 (enExample) |